Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA231-0000  |   NCT06476808

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

Summary

  • Phase 1
  • Male and Female Gender icon
  • 18+
    Age Range
  • 16
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
  • Participants must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.
    1. Participants must have at least 1 lesion accessible for biopsy in addition to the target lesion, from which a fresh pre treatment biopsy must be obtained.
      1. Participants must have an unresectable/metastatic carcinoma.

        Exclusion Criteria

        Exclusion Criteria Icon
        • Participants must not have Leptomeningeal metastases.
          1. Participants must not have concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to treatment.
            1. Participants must not have had any prior radiation therapy within 2 weeks prior to start of study treatment.
              Additional Information *
              • Other protocol-defined Inclusion/Exclusion criteria apply.

                Treatment Options

                Study Arms

                ASSIGNED INTERVENTION

                Study Arms

                Experimental: Arm 1: Dose Escalation

                ASSIGNED INTERVENTION
                • Drug: BMS-986463

                Study Arms

                Experimental: Arm 2: Dose Expansion

                ASSIGNED INTERVENTION
                • Drug: BMS-986463
                Take the first step to see if you Match to a Clinical Trial – Check if you qualify
                Check if you qualify
                Answer some questions about Your health to see if you may match to this trial
                Match to a Trial
                If you are a match, click on the study to see the list of study site locations
                Select a Study Site Location
                Select a study site location that is convenient for you
                Register
                Provide your contact details for the study site to connect with you.

                Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you